GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Median PS Value

Inotiv (Inotiv) Median PS Value : $15.54 (As of May. 13, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Inotiv's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $22.728. Inotiv's 10-Year median PS Ratio is 0.6837. Therefore, the Median PS Value for today is $15.54.

As of today (2024-05-13), Inotiv's share price is $4.1339. Inotiv's Median PS Value is $15.54. Therefore, Inotiv's Price to Median PS Value for today is 0.27.

The historical rank and industry rank for Inotiv's Median PS Value or its related term are showing as below:

NOTV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2   Med: 1.45   Max: 7.35
Current: 0.27

During the past 13 years, the highest Price to Median PS Value of Inotiv was 7.35. The lowest was 0.20. And the median was 1.45.

NOTV's Price-to-Median-PS-Value is ranked better than
89.02% of 82 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.81 vs NOTV: 0.27

Inotiv Median PS Value Historical Data

The historical data trend for Inotiv's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Median PS Value Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 3.27 4.13 15.68 15.74

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.25 16.50 15.99 15.74 15.54

Competitive Comparison of Inotiv's Median PS Value

For the Diagnostics & Research subindustry, Inotiv's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Inotiv's Price-to-Median-PS-Value falls into.



Inotiv Median PS Value Calculation

Inotiv's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=22.728*0.6837
=15.54

10-Year Median PS Ratio is 0.6837.
Inotiv's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.728.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inotiv  (NAS:NOTV) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Inotiv's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=4.1339/15.54
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inotiv Median PS Value Related Terms

Thank you for viewing the detailed overview of Inotiv's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065